Sugammadex-rocuronium dosing [17]

Anesthesia and Analgesia

Volumn 105, Issue 3, 2007, Pages 883-884

  Kopman, Aaron F ^a  

^a ST VINCENT S HOSPITAL MANHATTAN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ROCURONIUM; SUGAMMADEX;

HUMAN; LETTER; MOLECULAR WEIGHT; NEUROMUSCULAR BLOCKING; PRIORITY JOURNAL;

ANDROSTANOLS; GAMMA-CYCLODEXTRINS; MOLECULAR WEIGHT; NEUROMUSCULAR BLOCKADE; NEUROMUSCULAR NONDEPOLARIZING AGENTS;

EID: 34548140136     PISSN: 00032999     EISSN: None     Source Type: Journal    
DOI: 10.1213/01.ane.0000269685.86443.a8     Document Type: Letter

References (3)

1. Groudine SB, Soto R, Lien C, Drover D, Roberts K. A randomized, dose-finding, phase II study of the selective relaxant binding drug, sugammadex, capable of safely reversing profound rocuroniuminduced neuromuscular block. Anesth Analg 2007;104:555-62
2. Rex C, Khuenl-Brady K, Sielenkaemper A, Kjaer CC, Puehringer FK. Reversal of highdose rocuronium (1.2 mg/kg) with org 25969. Anesthesiology 2005;103:A1129
3. -1) neuromuscular block by org 25969: a multi center dose finding and safety study. Anesthesiology 2005;103:A1117